Senior Vice President
When it comes to market access strategy, there may be no better person to turn to than Jeremy Schafer, PharmD, MBA.
Under his leadership, he rebranded PRECISIONvalue’s strategy team the Access Experience Team and augmented the team’s experience beyond health plans and PBMs by adding individuals with prior roles at GPOs, specialty pharmacies, integrated delivery networks, and medical management companies. He also leads this team of approximately 20 individuals, which includes past leaders from organizations such as United Healthcare, Express Scripts, Prime Therapeutics, UPMC, Kaiser, Sutter Health, Aetna, Humana, and others. The result has been an array of strategic experiences that can be leveraged to solve life sciences companies’ most complex market access problems.
Jeremy also spearheaded the launch of “Precision Insights,” a newsletter authored by Access Experience Team advisors and customized to the client, requiring each advisor to evaluate the trends and offer personalized strategic guidance. Jeremy’s latest initiative, Access60, involves 60-second video clips where individual Access Experience Team advisors opine on a recent healthcare story or trend and offer quick insights via social media.
Jeremy has also been instrumental in the development of PRECISIONvalue products that have contributed to the industry. He helped enhance Rapid Pulse, a survey tool used by the company to gain insights from current payers and deliver summarized results and insights to life sciences customers within 72 hours. Jeremy published the findings of one survey in the JMCP, which demonstrated the value and scientific rigor that market agency research can contribute to the healthcare marketplace.
Jeremy’s perspectives on market access challenges have proven to be quite valued by those in the industry. He recently won the “40 under 40 in Cancer” award for his work in the oncology field, where he has been dedicated to improving access to cancer therapies for patients by leveraging his expertise in payer messaging and value communication. And his international perspective on how gene therapies are financed in the U.S. and Europe was highly valued by stakeholders at the inaugural Gene and Advanced Therapy: Creating Value in the Patient Journey and in the Health System conference in Brazil.